Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma

<div>Prognostic analysis of the 14-signature model in the training cohort and test cohort based on the TCGA database. (a) Prognostic lymphangiogenesis-related signature construction based on LASSO Cox analysis. (b) The coefficient and log2(HR) for these prognostic lymphangiogenesis-related signatures. Kaplan–Meier curves for the OS of patients in the high- and low-risk groups in the training cohort (c) and test cohort (d).</div>

Analytical Cellular Pathology

fig3

Figure 3

Figure 3: Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma 

Figure 3 | Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma 